Exploring Latin America In The COVID-19 Era
Unique industry partnerships and new regulatory flexibility in Latin America may help to improve access to medicines, even as COVID-19 wreaks havoc in the region’s largest pharmaceutical market. Can biopharma’s bespoke solutions to market access barriers coalesce into a strategy capable of overcoming political, economic and COVID-19 related risks?
You may also be interested in...
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.
Clinical-stage biopharma Starton Therapeutics is developing continuous delivery systems and transdermal technologies to improve the safety and efficacy of existing cancer medications, and eschewing VC firms in favor of retail investors. Chair and CEO Pedro Lichtinger recently appeared on Unicorn Hunters, an online reality TV show, to pitch the company to celebrity judges, and the public at large.
A panel of executives, academics and experts discussed the potential for psychedelic therapies, such as MDMA and psilocybin, to revolutionize behavioral health in a recent Demy Colton virtual salon. But with nearly 50 publicly traded companies now developing psychedelics, some panelists expressed concern about a rush to market, and “competition and domination” harshening the buzz.